Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Germline variants associated with toxicity to immune checkpoint blockade.
Groha S, Alaiwi SA, Xu W, Naranbhai V, Nassar AH, Bakouny Z, El Zarif T, Saliby RM, Wan G, Rajeh A, Adib E, Nuzzo PV, Schmidt AL, Labaki C, Ricciuti B, Alessi JV, Braun DA, Shukla SA, Keenan TE, Van Allen E, Awad MM, Manos M, Rahma O, Zubiri L, Villani AC, Fairfax B, Hammer C, Khan Z, Reynolds K, Semenov Y, Schrag D, Kehl KL, Freedman ML, Choueiri TK, Gusev A. Groha S, et al. Among authors: rahma o. Nat Med. 2022 Dec;28(12):2584-2591. doi: 10.1038/s41591-022-02094-6. Epub 2022 Dec 16. Nat Med. 2022. PMID: 36526723 Free PMC article.
Prospective Correlation of Magnetic Resonance Tumor Regression Grade With Pathologic Outcomes in Total Neoadjuvant Therapy for Rectal Adenocarcinoma.
Hall WA, Li J, You YN, Gollub MJ, Grajo JR, Rosen M, dePrisco G, Yothers G, Dorth JA, Rahma OE, Russell MM, Gross HM, Jacobs SA, Faller BA, George S, Al Baghdadi T, Haddock MG, Valicenti R, Hong TS, George TJ. Hall WA, et al. Among authors: rahma oe. J Clin Oncol. 2023 Oct 10;41(29):4643-4651. doi: 10.1200/JCO.22.02525. Epub 2023 Jul 21. J Clin Oncol. 2023. PMID: 37478389
Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer.
Duffy AG, Makarova-Rusher OV, Ulahannan SV, Rahma OE, Fioravanti S, Walker M, Abdullah S, Raffeld M, Anderson V, Abi-Jaoudeh N, Levy E, Wood BJ, Lee S, Tomita Y, Trepel JB, Steinberg SM, Revenko AS, MacLeod AR, Peer CJ, Figg WD, Greten TF. Duffy AG, et al. Among authors: rahma oe. Int J Cancer. 2016 Oct 1;139(7):1648-57. doi: 10.1002/ijc.30199. Epub 2016 Jun 27. Int J Cancer. 2016. PMID: 27194579 Free PMC article. Clinical Trial.
Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma.
Duffy AG, Ma C, Ulahannan SV, Rahma OE, Makarova-Rusher O, Cao L, Yu Y, Kleiner DE, Trepel J, Lee MJ, Tomita Y, Steinberg SM, Heller T, Turkbey B, Choyke PL, Peer CJ, Figg WD, Wood BJ, Greten TF. Duffy AG, et al. Among authors: rahma oe. Clin Cancer Res. 2017 Aug 15;23(16):4633-4641. doi: 10.1158/1078-0432.CCR-16-3171. Epub 2017 May 2. Clin Cancer Res. 2017. PMID: 28465443 Free PMC article. Clinical Trial.
Current debate in the oncologic management of rectal cancer.
Millard T, Kunk PR, Ramsdale E, Rahma OE. Millard T, et al. World J Gastrointest Oncol. 2016 Oct 15;8(10):715-724. doi: 10.4251/wjgo.v8.i10.715. World J Gastrointest Oncol. 2016. PMID: 27795811 Free PMC article. Review.
A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib.
Duffy AG, Ulahannan SV, Cao L, Rahma OE, Makarova-Rusher OV, Kleiner DE, Fioravanti S, Walker M, Carey S, Yu Y, Venkatesan AM, Turkbey B, Choyke P, Trepel J, Bollen KC, Steinberg SM, Figg WD, Greten TF. Duffy AG, et al. Among authors: rahma oe. United European Gastroenterol J. 2015 Oct;3(5):453-61. doi: 10.1177/2050640615583587. United European Gastroenterol J. 2015. PMID: 26535124 Free PMC article.
91 results